Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Refsum disease--rare, but world-famous].

O Stokke1

  • 1Institutt for klinisk biokjemi Universitetet i Oslo Rikshospitalet 0027 Oslo. oddvar.halldor.stokke@rikshospitalet.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|March 13, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serial ultrasensitive CRP measurements may be useful in rejection diagnosis after kidney transplantation.

Transplantation proceedings·2001
Same author

MicroCRP: a highly sensitive CRP method applied in the monitoring of renal allograft recipients.

Scandinavian journal of clinical and laboratory investigation·1999
Same author

[Measurements of N-terminal proatrial natriuretic factor in children].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·1999
Same author

Elevation of atrial natriuretic peptide prohormone. Hemodynamic background of the elevation of N-terminal natriuretic peptide prohormone in children with congenital heart disease.

Cardiology in the young·1999
Same author

Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation.

Transplantation·1998
Same author

Molecular basis of Refsum disease: identification of new mutations in the phytanoyl-CoA hydroxylase cDNA.

Journal of inherited metabolic disease·1998

Sigvald Refsum identified a new neurodegenerative disorder, now known as Refsum's disease. Biochemical analysis later revealed its cause: phytanic acid accumulation, leading to effective treatments.

Area of Science:

  • Neurology
  • Biochemistry
  • Genetics

Background:

  • Sigvald Bernhard Refsum, a Norwegian neurologist, clinically described a novel neurodegenerative disease in 1946, initially termed 'heredopathia atactica polyneuritiformis'.
  • This condition, commonly known as Refsum's disease, presented with a complex array of neurodegenerative symptoms.
  • Refsum's meticulous clinical observations laid the groundwork for future etiological investigations.

Discussion:

  • The discovery of Refsum's disease was significantly advanced by the detection of high levels of phytanic acid in affected patients.
  • This finding by Klenk and Kahlke initiated a deeper understanding of the disease's biochemical underpinnings.
  • The identification of phytanic acid's role was crucial for unraveling the pathophysiology of this rare genetic disorder.

Key Insights:

Related Experiment Videos

  • Refsum's disease is characterized by the accumulation of phytanic acid, a branched-chain fatty acid.
  • The elucidation of phytanic acid metabolism provided critical insights into the disease's molecular mechanisms.
  • This biochemical understanding paved the way for targeted and effective therapeutic strategies.

Outlook:

  • Further research into phytanic acid metabolism continues to refine treatment protocols for Refsum's disease.
  • Understanding the genetic basis of Refsum's disease may reveal broader implications for other metabolic or neurodegenerative disorders.
  • Continued investigation into rare diseases like Refsum's disease highlights the importance of interdisciplinary approaches in medical science.